Chapel Hill, NC. (Business Wire)  January 21, 2016 – Asklepios BioPharmaceutical, Inc. (AskBio) has entered into a license agreement granting Calimmune Inc. rights to AskBio’s Adeno-Associated Virus (AAV) gene therapy technologies. Charlie Turner, TCG Partner, led the completion of the license for the osteoarthritis area as AskBio’s lead Business Development Representative.  AskBio’s advanced AAV-based gene vector delivery technologies currently support over a dozen active INDs.

Calimmune, a gene therapy company focused on enhancing patients’ immune systems to defeat disease, plans to utilize these technologies in a forthcoming Phase I/II clinical trial to evaluate the safety and efficacy of a potential gene therapy for the treatment of osteoarthritis. Currently over 27 million Americans suffer from osteoarthritis, a chronic, degenerative disease of the joints, which is incurable and difficult to treat.

http://www.businesswire.com/news/home/20160112005214/en/Asklepios-BioPharmaceutical-Enters-License-Agreement-Calimmune#.VpUFtqbaIN4.gmail